Recombinant mAbs for SARS-CoV-2 Research
Monoclonal antibodies (mAbs) against SARS-CoV-2 antigens or host pro-inflammatory cytokine receptors are under therapeutic investigation for fighting COVID-19.
InvivoGen offers isotype families of recombinant mAbs related to COVID-19 research.
Anti-SARS-CoV-2 Spike mAbs: target the SARS-CoV-2 RBD
— CR3022-derived antibodies
— H4-derived antibodies
— B38-derived antibodies
— REGN-10933 & REGN-10987-derived antibodies
— LY-CoV555 & LY-CoV016-derived antibodies
Anti-SARS-CoV-2 Nucleocapsid mAb: targets the SARS-CoV-2 Nucleocapsid
— CR3018-derived antibody
Anti-hIL-6R mAbs: target the human interleukin-6 receptor
— Tocilizumab-derived antibodies
These antibodies are available with different immunoglobulin isotypes, either native or engineered. The different isotypes can trigger or hinder mAb effector functions including, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity or phagocytosis (ADCC or ADCP). Depending on your target and application, InvivoGen offers:
- Human isotypes
hIgG1: highly-represented in the serum and a potent inducer of ADCC, ADCP, and CDC
hIgG1NQ: non-glycosylated hIgG1 exhibiting ablated ADCC and ADCP, as well as severely compromised CDC
hIgA: main antibody isotype present in mucosal secretions (i.e. in the respiratory tract) and a moderate inducer of ADCC and ADCP
hIgM: first antibody isotype raised in the immune response and a potent inducer of CDC
- Mouse isotypes
mIgG2a: most potent inducer of ADCC, ADCP, and CDC among murine isotypes
mIgG1e3: effectorless mIgG1 with a D265A point mutation
As a guarantee of quality, our antibody constructs are fully sequenced and their target binding has been validated.
InvivoGen’s products are for research use only, and not for clinical or veterinary use.